The Munich techbio company is developing a live bacterial product designed to enhance immune checkpoint inhibitor response in advanced melanoma, with a Phase 1B study planned for 2027 mbiomics GmbH , a Munich-based techbio company developing microbiome-based therapeutics, has completed the third and final closing of its Series A funding round, bringing the total raised to €30 million. The latest €12 million tranche was provided by existing investors MIG Fonds and Bayern Kapital, and marks the conclusion of a round that began in March 2023. The capital will fund two near-term priorities: strengthening the IND-enabling pharmacological data package for the company’s lead candidate MBX-116, and accelerating the GMP-grade manufacturing development required to produce it at the clinical scale needed for human trials. The goal is a Phase 1B study in second-line advanced melanoma, planned to begin in 2027.…